* If you want to update the article please login/register
Peripartum cardiomyopathy is a rare but potentially life-threatening form of heart disease. We included reviews comparing the results of PPCM with or without bromocriptine use. At a 6-month follow-up, composite major adverse events were defined by a mixture of death, the need for advanced HF therapies, persistent New York Heart Association functional class III/V, or left ventricular ejection fraction 35%. The LVEF recovery was defined by LVEF's rise to more than 50%. Eight studies involving 593 PPCM patients were included. Bromocriptine use was correlated with a significant rise in survival. There was no significant correlation between bromocriptine use in lower composite major adverse effects or LVEF recovery, according to the researchers. In conclusion, the addition of bromocriptine to standard HF therapy in PPCM resulted in significantly higher survival and increased LVEF improvement. No association was found between lower composite adverse clinical findings or LVEF recovery.
Source link: https://doi.org/10.1007/s10741-021-10185-8
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions